Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX 12:18:48 2024-03-28 pm EDT 5-day change 1st Jan Change
131.7 USD -0.06% Intraday chart for Merck & Co., Inc. +6.59% +20.87%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Merck: new indication approved for Keytruda in Europe CF
Merck Says Keytruda Plus Chemotherapy as Neoadjuvant Treatment Receives Approval From European Commission MT
European Commission Approves Merck?s Keytruda® (Pembrolizumab) Plus Chemotherapy CI
Alliance Defending Freedom Files Exempt Solicitation Statement with Securities and Exchange Commission CI
S&P 500 Closes at Record High Ahead of Thursday's Economic Data MT
Sector Update: Health Care Stocks Advance Late Afternoon MT
Shares cautiously climb; Japan officials rattle sabers at yen shorts RE
Merck's Winrevair Poised for Strong Launch Following US FDA Approval, UBS Says MT
Dow leads gains on Wall Street as investors await rate clues RE
Sector Update: Health Care Stocks Gain Wednesday Afternoon MT
Sector Update: Health Care MT
Utilities, Real Estate Push US Equity Indexes Higher Ahead of Fed Governor Waller's Speech MT
Global markets live: Apple, UBS, Microstrategy, Merck, Amazon... Our Logo
US Equity Indexes Rise, Treasury Yields Fall in Midday Trading MT
Top Midday Stories: Disney, DeSantis Reach Settlement; Judge Allows SEC's Coinbase Lawsuit to Proceed; UBS Sells Credit Suisse Assets to Apollo; Online Betting Platforms Form Group to Tackle Problem Gambling; EU Rejects Amazon Bid to Suspend Advertising Clause; Moderna to Receive $750 Million from Blackstone; Merck Drug Gets FDA Approval MT
Merck: share price soars after FDA green light CF
Truist Securities Raises Merck Price Target to $142 From $139, Maintains Buy Rating MT
Trending : Merck Wins FDA Green Light for Winrevair DJ
Focus on Waller, PCE and Powell Our Logo
Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday MT
Wall St set to open higher as growth stocks recover RE
Wells Fargo Raises Price Target on Merck to $135 From $130, Maintains Equal-Weight Rating MT
Merck Receives FDA Approval for Winrevair as Hypertension Treatment MT
Futures recover; focus shifts to Fed officials' comments RE
Merck: Winrevair approved in the United States CF
Chart Merck & Co., Inc.
More charts
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
131.8 USD
Average target price
136.2 USD
Spread / Average Target
+3.38%
Consensus
  1. Stock
  2. Equities
  3. Stock Merck & Co., Inc. - Nyse
  4. News Merck & Co., Inc.
  5. Merck & Co.'s Keytruda Fails To Extend Survival In Liver, Prostate Cancer Studies